Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonja Ingrid Kroschwald

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Oncology Letters|June 22, 2026
Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Oncology Letters|August 20, 2019
Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Oncology Letters|June 22, 2026
Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Oncology Letters|August 20, 2019
Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>Lysann Michaela Kroschwald, Josephine Tabea Tauer, Sonja Ingrid Kroschwald, et al.
Pageof 1